Comparison of in vitro activities of tigecycline with other antimicrobial agents against streptococcus pneumoniae,haemophilus influenzae and moraxella catarrhalis in two university hospitals in Istanbul, Turkey

Chemotherapy

Volumn 55, Issue 3, 2009, Pages 161-167

  Gonullu, Nevriye ^a   Catal, Fadimana ^a   Kucukbasmaci, Omer ^a   Ozdemir, Sinem ^a   Torun, Muzeyyen Mamal ^a   Berkiten, Rahmiye ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antibiotic resistance; Haemophilus influenzae; Moraxella catarrhalis; Streptococcus pneumoniae; Tigecycline

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE; TIGECYCLINE;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HAEMOPHILUS INFLUENZAE; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MORAXELLA (BRANHAMELLA) CATARRHALIS; STREPTOCOCCUS PNEUMONIAE; TURKEY;

EID: 65449122011     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000214144     Document Type: Article

References (25)

1. Felmingham D, Cantón R, Jenkins SG:Regional trends in β-lactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007;55:111-118.
2. Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C:Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy 2009;55:20-27.
3. Lau YJ, Hsueh PR, Liu YC, Shyr JM, Huang WK, Teng LJ, Liu CY, Luh KT:Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Taiwan. Microb Drug Resist 2006;12:130-135.
4. Fritsche TR, Kirby JT, Jones RN:In vitro activity of tigecycline (GAR-936) tested against 11859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diag Microbiol Infect Dis 2004;49:201-209.
5. Brown SD, Traczewski MM:Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control. J Clin Microbiol 2007;45:2173-2179.
6. Pinar A, Köseoǧlu Ö, Yenişehirli G, Şener B:Molecular epidemiology of penicillin-resistant Streptococcus pneumoniae in a university hospital, Ankara, Turkey. Clin Microbiol Infect 2004;10:718-723.
7. Turnak MR, Bandak SI, Bouchillon SK, Allen BS, Hoban DJ:Antimicrobial susceptibilities of clinical isolates of Haemophilus inf luenzae and Moraxella catarrhalis col lected during 1999-2000 from 13 countries. Clin Microbiol Infect 2001;7:671-677.
8. Gür D, Özalp M, Sümerkan B, Kaygusuz A, Töreci K, Köksal İ, Över U, Söyletir G:Prevalence of antimicrobial resistance in Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and Streptococcus pyogenes:results of a multicentre study in Turkey. Int J Antimicrob Agents 2002;19:207-211.
9. Küçükbasmaci Ö, Gönüllü N, Aktaş Z, Gürol D, Berkiten R:In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Int J Antimicrob Agents 2003;22:497-501.
10. Yagci A, Ilki A, Akbenlioglu C, Ulger N, Inanli S, Söyletir G:Surveillance of Haemophilus influenzae among respiratory tract samples of Turkish children. Int J Antimicrob Agents 2003;22:548-550.
11. Zarakolu P, Soyletir G, Gur D, Unal S:Antimicrobial resistance patterns of respiratory pathogens:a local report from Turkey. Clin Microb Infect 2003;9:1257-1258.
12. Ozyilmaz E, Akan OA, Gulhan M, Ahmed K, Nagatake T:Major bacteria of community-acquired respiratory tract infections in Turkey. Jpn J Infect Dis 2005;58:50-52.
13. Şener B, Tunçkanat F, Ulusoy S, Tünger A, Söyletir G, Mülazimoǧlu L, Gürler N, Öksüz L, Köksal İ, Aydin K, Yalçin AN, Öǧünç D, Acar A, Sievers J:A survey of antibiotic resistance in Streptococcus pneumoniae and Haemophilus influenzae in Turkey, 2004-2005. J Antimicrob Chemother 2007;60:587-593.
14. Clinical and Laboratory Standards Institute:Performance Standards for Antimicrobial Susceptibility Testing, 17th Informational Supplement, M100-S17. Clinical and Laboratory Standards Institute, Wayne, 2007.
15. European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2007. http://www.earss.rivm.nl.
16. Betriu C, Rodriguez-Avial I, Gómez M, Culebras E, López F, Álvarez J, Picazo JJ, the Spanish Tigecycline Group:Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diag Microbiol Infect Dis 2006;56:437-444.
17. Roveta S, Marchese A, Debbia EA:Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy. Chemotherapy 2008;54:43-49.
18. Draghi DC, Tench S, Dowzicky MJ, Sahm DF:Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance. Chemotherapy 2008;54:91-100.
19. Hoban D, Felmingham D:The PROTEKT surveillance study:antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections. J Antimicrob Chemother 2002;50:49-59.
20. Fluit AC, Florijn A, Verhoef J, Milatovic D:Susceptibility of European β-lactamase-positive and -negative Haemophilus influenzae isolates from the periods 1997/1998 and 2002/2003. J Antimicrob Chemother 2005;56:133-138.
21. Semczuk K, Dzierzanowska-Fangrat K, Lopaciuk U, Gabinska E, Jozwiak P, Dzierzanowska D:Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from children with community-acquired respiratory tract infections in Central Poland. Int J Antimicrob Agents 2004;23:39-43.
22. Gracia M, Diaz C, Coronel P, Gimeno M, Garcia-Rodas R, del Prado G, Huelves L, Ruiz V, Naves PL, Ponte MC, Granizo JJ, Soriano F:Antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis isolates in eight Central, East and Baltic European countries in 2005-06:results of the Cefditoren Surveillance Study. J Antimicrob Chemother 2008;61:1180 -1185.
23. Walsh F, Carnegy F, Willcock J, Amyes S:Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 2004;53:793-796.
24. Bradford PA, Petersen PJ, Tuckman M, Jones CH:In vitro activity of tigecycline and occurrence of tetracycline resistance determinants in isolates from patients enrolled in phase 3 clinical trials for community-acquired pneumonia. Clin Microbiol Infect 2008;14:882-886.
25. Gales AC, Jones RN, Andrade SS, Pereira AS, Sader HS:In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America. Braz J Infect Dis 2005;9:348-356.